Subsequent Events - Additional Information (Detail)											1 Months Ended	12 Months Ended
	Dec. 29, 2016 USD ($) shares	Sep. 28, 2016 USD ($)	Sep. 23, 2016 $ / shares shares	Jul. 05, 2016 USD ($) shares	Jun. 23, 2016 USD ($)	Jun. 07, 2016 USD ($) Employee Tranche shares	Jun. 06, 2016 USD ($)	May 04, 2016 USD ($)	Jul. 22, 2015 $ / shares shares	Apr. 04, 2013 USD ($) $ / shares shares	Oct. 31, 2005 USD ($)	Dec. 29, 2016 USD ($) shares	Dec. 31, 2015 USD ($) shares	Dec. 31, 2014 USD ($) shares
Subsequent Event [Line Items]
Technology transaction fees											$ 4,000,000
Milestone payment obligated as sale of product											$ 10,000,000
Royalty percentage on net sales											5.00%
Royalties to net sales of other product											4.00%
Common stock, shares outstanding | shares													13,187,544	12,775,044
Total base rent over the lease term													$ 222,736
Related party transaction, net expenses paid by chief executive officer													$ 946,142	$ 688,433
Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Common stock, shares outstanding | shares									16,656,348				13,187,544
Increase in common stock outstanding, percentage									26.00%
Granted common stock purchase warrants | shares									3,585,908
Additional warrant shares to be granted | shares									3,749,692
Common stock purchase warrants outstanding with anti-dilutive provisions | shares									7,235,600
Weighted average price of warrant | $ / shares									$ 0.71
Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized | shares													40,000,000	40,000,000
Series A Convertible Preferred stock, shares outstanding | shares													1,041	1,176
Preferred stock converted into common stock | shares													3,468,804	1,826,381
Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Series A Convertible Preferred stock, shares outstanding | shares									1,176
Effective conversion price per share | $ / shares									$ 0.30
Stated value per share for redemption | $ / shares									$ 1,000
Preferred stock converted into common stock | shares									3,918,667
Additional preferred stock converted into common stock | shares									2,092,350
Chief Executive Officer [Member]
Subsequent Event [Line Items]
Related party transaction, net expenses paid by chief executive officer													$ 946,142
Angionetics Inc. [Member] | Mainland China [Member] | Pineworld Capital Limited [Member]
Subsequent Event [Line Items]
Royalty payment period													quarterly
Royalty description													The royalty payments commence on the first commercial sale and expire on the earlier of the termination of any patent or regulatory exclusivity in China or fifteen years after the first commercial sale. The term of the agreement continues (unless terminated for breach) until Huapont’s affiliate has no remaining payment obligations to Angionetics.
Minimum [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share | $ / shares									$ 0.30
Maximum [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share | $ / shares									$ 0.64
Schering AG Technology Transfer Agreement [Member]
Subsequent Event [Line Items]
Technology transaction fees													$ 4,000,000
Milestone payment obligated as sale of product													$ 10,000,000
Share Purchase Agreement [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized | shares										4,012
Effective conversion price per share | $ / shares										$ 0.6437
Share Purchase Agreement [Member] | Maximum [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Proceeds from issuance of preferred stock										$ 4,000,000
Subsequent Event [Member] | Office Lease [Member]
Subsequent Event [Line Items]
Lease agreement term					38 months
Monthly base rent in year one					$ 3,500
Monthly base rent in year two					3,700
Monthly base rent in year three					3,800
Monthly base rent in the final two months of the agreement					3,900
Total base rent over the lease term					$ 139,800
Subsequent Event [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Common stock, shares outstanding | shares	18,878,218		13,723,544									18,878,218
Increase in common stock outstanding, percentage	38.00%
Granted common stock purchase warrants | shares			7,235,600
Additional warrant shares to be granted | shares			4,823,733
Common stock purchase warrants outstanding with anti-dilutive provisions | shares			12,059,333
Weighted average price of warrant | $ / shares			$ 0.71
Subsequent Event [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Series A Convertible Preferred stock, shares outstanding | shares	928		1,000									928
Effective conversion price per share | $ / shares			$ 0.18
Stated value per share for redemption | $ / shares			$ 1,000
Preferred stock redemption date			Nov. 29, 2016
Preferred stock converted into common stock | shares	5,154,674		5,554,667									5,154,674
Additional preferred stock converted into common stock | shares			2,221,867
Subsequent Event [Member] | Pineworld Capital Limited [Member]
Subsequent Event [Line Items]
Anti-dilution protection of equity interest						15.00%
Anti-dilution protection of post-money valuation						$ 20,000,000
Number of tranches | Tranche						2
Subsequent Event [Member] | Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Initial Tranche [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized | shares				200,000
Proceeds from issuance of preferred stock				$ 1,000,000
Subsequent Event [Member] | Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member] | Second Tranche [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized | shares						400,000
Proceeds from issuance of preferred stock						$ 2,000,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Subsequent Event [Line Items]
Related party transaction, net expenses paid by chief executive officer	$ 1,058,142											$ 1,058,142
Additions to related party transaction, net expenses paid by chief executive officer												$ 112,086
Subsequent Event [Member] | Angionetics Inc. [Member] | Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Percentage of stock convertible at pro rata basis						15.00%
Preferred stock conversion basis						The Shares are initially convertible on a one to one basis into Angionetics common stock.
Subsequent Event [Member] | Angionetics Inc. [Member] | Pineworld Capital Limited [Member] | Second Tranche [Member]
Subsequent Event [Line Items]
Proceeds from issuance of preferred stock		$ 2,000,000
Subsequent Event [Member] | Angionetics Inc. [Member] | Mainland China [Member] | Pineworld Capital Limited [Member]
Subsequent Event [Line Items]
Royalty expiration period						15 years
Subsequent Event [Member] | Angionetics Inc. [Member] | Services Agreement [Member]
Subsequent Event [Line Items]
Facilities costs payment percentage							70.00%
Subsequent Event [Member] | Huapont Life Sciences [Member]
Subsequent Event [Line Items]
Revenues						$ 1,100,000,000
Subsequent Event [Member] | Huapont Life Sciences [Member] | Shenzhen Stock Exchange [Member]
Subsequent Event [Line Items]
Current market capitalization						$ 3,000,000,000
Subsequent Event [Member] | Huapont Life Sciences [Member] | Mainland China [Member]
Subsequent Event [Line Items]
Number of employees | Employee						7,100
Subsequent Event [Member] | Minimum [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share | $ / shares			$ 0.18
Subsequent Event [Member] | Minimum [Member] | Angionetics Inc. [Member] | Mainland China [Member] | Pineworld Capital Limited [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales						5.00%
Subsequent Event [Member] | Maximum [Member] | Series A Convertible Preferred Stock [Member] | Exchange and Redemption Agreement with Sabby Healthcare Volatility Master Fund, Ltd. [Member]
Subsequent Event [Line Items]
Effective conversion price per share | $ / shares			$ 0.30
Subsequent Event [Member] | Maximum [Member] | Angionetics Inc. [Member] | Mainland China [Member] | Pineworld Capital Limited [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales						10.00%
Subsequent Event [Member] | Contribution Agreement [Member] | Angionetics Inc. [Member]
Subsequent Event [Line Items]
Technology fee payable upon earlier of qualified initial public offering							$ 2,000,000
Shares lock up period							12 months
Subsequent Event [Member] | Contribution Agreement [Member] | Minimum [Member] | Angionetics Inc. [Member]
Subsequent Event [Line Items]
Percentage of outstanding capital stock							9.99%
Subsequent Event [Member] | Bayer Pharma AG [Member] | Angionetics Inc. [Member]
Subsequent Event [Line Items]
Milestone payment obligated as sale of product								$ 0
Transfer agreement description								Bayer Pharma AG agreed to the transfer of the Technology Transfer Agreement from Taxus Cardium to Angionetics. Accordingly, Angionetics has assumed the obligation for any milestone payment required to be paid to Bayer Pharma AG.
Royalty percentage on net sales								5.00%
Royalties to net sales of other product								4.00%
Sales under transfer agreement								$ 0
Subsequent Event [Member] | Bayer Pharma AG [Member] | Angionetics Inc. [Member] | FGF-4 Based Product Without Infringe Patent [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales								2.50%
Subsequent Event [Member] | Bayer Pharma AG [Member] | Angionetics Inc. [Member] | Other Products Without Infringe Patent [Member]
Subsequent Event [Line Items]
Royalty percentage on net sales								2.00%
Subsequent Event [Member] | Share Purchase Agreement [Member] | Angionetics Inc. [Member] | Pineworld Capital Limited [Member] | Series A Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares authorized | shares						600,000
Proceeds from issuance of preferred stock						$ 3,000,000